Picture of BioCryst Pharmaceuticals logo

BCRX — BioCryst Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

BioCryst Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

* BioCryst Pharmaceuticals Inc  BCRX.OQ  reported a
quarterly
adjusted loss of 6 cents​​ per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -24 cents.  The mean expectation of
eleven analysts for the quarter was for a loss of 17 cents per
share. Wall Street expected results to range from -32 cents
to -14 cents per share.
    * Revenue rose 32.5% to $109.33 million from a year ago;
analysts
expected $98.32 million. 
    * BioCryst Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 6 cents​.
    * The company reported a quarterly loss of $12.67 million.
    * BioCryst Pharmaceuticals Inc shares had risen by 13.6%
this
quarter and gained 17.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $11.00 
This summary was machine generated from LSEG data August 5 at
01:51 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.17          -0.06          Beat
 Mar. 31 2024      -0.21          -0.17          Beat
 Dec. 31 2023      -0.24          -0.28          Missed
 Sep. 30 2023      -0.23          -0.19          Beat

Recent news on BioCryst Pharmaceuticals

See all news